Yau C. Yun, David R. Santiago-Dieppa, Minghao Li, Aditya Vasan, Alexander Khalessi, James Friend
{"title":"通过集成软机器人装置治疗脑积水的不可堵塞脑室-腹膜分流系统:清除装置。","authors":"Yau C. Yun, David R. Santiago-Dieppa, Minghao Li, Aditya Vasan, Alexander Khalessi, James Friend","doi":"10.1007/s10544-025-00769-8","DOIUrl":null,"url":null,"abstract":"<div><p>Ventriculoperitoneal (VP) shunt obstruction, often caused by protein and fat accumulation at the ventricular catheter ports, impedes cerebrospinal fluid (CSF) outflow, increases intracranial pressure (ICP), and leads to hydrocephalus. Current treatments require invasive shunt removal, reimplantation, or retrograde flush cleansing. We present a next-generation VP shunt system that actively removes blockages via external actuation. Our system, called CLogging Elimination ActuatoR Silicone (CLEARS), integrates a soft, expandable silicone tube within the catheter lumen. This soft robotic insert, capable of 900% strain, can inflate to dislodge blockages and then deflate to restore flow. To test CLEARS, we developed an ex vivo model simulating CSF flow and obstruction using a rapidly acting clogging agent. ICP upstream of the catheter was monitored to evaluate performance. When obstructed with 3 g of the clogging agent, ICP rose to 30 cmH<span>\\(_2\\)</span>O. Upon CLEARS activation, the silicone insert expanded through catheter ports and successfully removed the clog, restoring baseline ICP (<span>\\(\\sim\\)</span>0 cmH<span>\\(_2\\)</span>O) within approximately 40 s. Without the system, obstruction persisted and pressure remained elevated. Visual documentation confirmed the mechanism of action. The CLEARS system offers a promising solution to VP shunt occlusion by enabling non-invasive mechanical declogging. Our model replicates shunt obstruction and CSF dynamics, providing a testbed for device evaluation. The expandable insert maintained catheter flow and reduced ICP to normal levels after obstruction, representing a potential shift in how hydrocephalus is treated.</p></div>","PeriodicalId":490,"journal":{"name":"Biomedical Microdevices","volume":"27 3","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s10544-025-00769-8.pdf","citationCount":"0","resultStr":"{\"title\":\"Uncloggable ventriculoperitoneal shunt system for hydrocephalus via an integrated soft robotic device: CLEARS device\",\"authors\":\"Yau C. Yun, David R. Santiago-Dieppa, Minghao Li, Aditya Vasan, Alexander Khalessi, James Friend\",\"doi\":\"10.1007/s10544-025-00769-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ventriculoperitoneal (VP) shunt obstruction, often caused by protein and fat accumulation at the ventricular catheter ports, impedes cerebrospinal fluid (CSF) outflow, increases intracranial pressure (ICP), and leads to hydrocephalus. Current treatments require invasive shunt removal, reimplantation, or retrograde flush cleansing. We present a next-generation VP shunt system that actively removes blockages via external actuation. Our system, called CLogging Elimination ActuatoR Silicone (CLEARS), integrates a soft, expandable silicone tube within the catheter lumen. This soft robotic insert, capable of 900% strain, can inflate to dislodge blockages and then deflate to restore flow. To test CLEARS, we developed an ex vivo model simulating CSF flow and obstruction using a rapidly acting clogging agent. ICP upstream of the catheter was monitored to evaluate performance. When obstructed with 3 g of the clogging agent, ICP rose to 30 cmH<span>\\\\(_2\\\\)</span>O. Upon CLEARS activation, the silicone insert expanded through catheter ports and successfully removed the clog, restoring baseline ICP (<span>\\\\(\\\\sim\\\\)</span>0 cmH<span>\\\\(_2\\\\)</span>O) within approximately 40 s. Without the system, obstruction persisted and pressure remained elevated. Visual documentation confirmed the mechanism of action. The CLEARS system offers a promising solution to VP shunt occlusion by enabling non-invasive mechanical declogging. Our model replicates shunt obstruction and CSF dynamics, providing a testbed for device evaluation. The expandable insert maintained catheter flow and reduced ICP to normal levels after obstruction, representing a potential shift in how hydrocephalus is treated.</p></div>\",\"PeriodicalId\":490,\"journal\":{\"name\":\"Biomedical Microdevices\",\"volume\":\"27 3\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s10544-025-00769-8.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomedical Microdevices\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s10544-025-00769-8\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENGINEERING, BIOMEDICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical Microdevices","FirstCategoryId":"5","ListUrlMain":"https://link.springer.com/article/10.1007/s10544-025-00769-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
Uncloggable ventriculoperitoneal shunt system for hydrocephalus via an integrated soft robotic device: CLEARS device
Ventriculoperitoneal (VP) shunt obstruction, often caused by protein and fat accumulation at the ventricular catheter ports, impedes cerebrospinal fluid (CSF) outflow, increases intracranial pressure (ICP), and leads to hydrocephalus. Current treatments require invasive shunt removal, reimplantation, or retrograde flush cleansing. We present a next-generation VP shunt system that actively removes blockages via external actuation. Our system, called CLogging Elimination ActuatoR Silicone (CLEARS), integrates a soft, expandable silicone tube within the catheter lumen. This soft robotic insert, capable of 900% strain, can inflate to dislodge blockages and then deflate to restore flow. To test CLEARS, we developed an ex vivo model simulating CSF flow and obstruction using a rapidly acting clogging agent. ICP upstream of the catheter was monitored to evaluate performance. When obstructed with 3 g of the clogging agent, ICP rose to 30 cmH\(_2\)O. Upon CLEARS activation, the silicone insert expanded through catheter ports and successfully removed the clog, restoring baseline ICP (\(\sim\)0 cmH\(_2\)O) within approximately 40 s. Without the system, obstruction persisted and pressure remained elevated. Visual documentation confirmed the mechanism of action. The CLEARS system offers a promising solution to VP shunt occlusion by enabling non-invasive mechanical declogging. Our model replicates shunt obstruction and CSF dynamics, providing a testbed for device evaluation. The expandable insert maintained catheter flow and reduced ICP to normal levels after obstruction, representing a potential shift in how hydrocephalus is treated.
期刊介绍:
Biomedical Microdevices: BioMEMS and Biomedical Nanotechnology is an interdisciplinary periodical devoted to all aspects of research in the medical diagnostic and therapeutic applications of Micro-Electro-Mechanical Systems (BioMEMS) and nanotechnology for medicine and biology.
General subjects of interest include the design, characterization, testing, modeling and clinical validation of microfabricated systems, and their integration on-chip and in larger functional units. The specific interests of the Journal include systems for neural stimulation and recording, bioseparation technologies such as nanofilters and electrophoretic equipment, miniaturized analytic and DNA identification systems, biosensors, and micro/nanotechnologies for cell and tissue research, tissue engineering, cell transplantation, and the controlled release of drugs and biological molecules.
Contributions reporting on fundamental and applied investigations of the material science, biochemistry, and physics of biomedical microdevices and nanotechnology are encouraged. A non-exhaustive list of fields of interest includes: nanoparticle synthesis, characterization, and validation of therapeutic or imaging efficacy in animal models; biocompatibility; biochemical modification of microfabricated devices, with reference to non-specific protein adsorption, and the active immobilization and patterning of proteins on micro/nanofabricated surfaces; the dynamics of fluids in micro-and-nano-fabricated channels; the electromechanical and structural response of micro/nanofabricated systems; the interactions of microdevices with cells and tissues, including biocompatibility and biodegradation studies; variations in the characteristics of the systems as a function of the micro/nanofabrication parameters.